Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of P-Cymene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | TYR | P14679 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| P-Cymene SCHEMBL5179600 | 1.00 | ACHE (0.47) | ACHETDP1CHRNA7BCHETYR | |
| P-Cymene SCHEMBL30110903 | 0.97 | ACHE (0.50) | ACHETDP1CHRNA7BCHETYR | |
| P-Cymene SCHEMBL30953569 | 0.97 | ACHE (0.50) | ACHETDP1CHRNA7BCHETYR | |
| P-Cymene SCHEMBL31300110 | 0.97 | ACHE (0.50) | ACHETDP1CHRNA7BCHETYR | |
| P-Cymene SCHEMBL23388160 | 0.94 | ACHE (0.47) | ACHETDP1CHRNA7BCHETYR | |
| P-Cymene SCHEMBL7865320 | 0.94 | ACHE (0.47) | ACHETDP1CHRNA7BCHETYR | |
| P-Cymene SCHEMBL30844107 | 0.94 | ACHE (0.47) | ACHETDP1CHRNA7BCHETYR | |
| P-Cymene SCHEMBL14954258 | 0.94 | ACHE (0.47) | ACHETDP1CHRNA7BCHETYR | |
| P-Cymene SCHEMBL23388162 | 0.94 | ACHE (0.47) | ACHETDP1CHRNA7BCHETYR | |
| P-Cymene SCHEMBL14954060 | 0.94 | ACHE (0.47) | ACHETDP1CHRNA7BCHETYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119751241-A | Preparation method of biphenyl-2-carboxylic acid compound at room temperature | 扬州大学 | 2025-04-04 | — | — | CN | claimed |
| CN-118791529-A | Dual-emission metal ruthenium complex probe and preparation method and application thereof | 华侨大学 | 2024-10-18 | — | — | CN | claimed |
| CN-118406010-A | Polysubstituted 1-amino isoquinoline derivative and synthesis method thereof | 商洛学院 | 2024-07-30 | — | — | CN | claimed |
| CN-117466721-A | Method for synthesizing difluoro cyclobutenone based on ruthenium catalytic carbonylation reaction | 陕西先氟领创科技有限公司 | 2024-01-30 | — | — | CN | claimed |
| CN-111961088-B | Method for preparing cis-bis (2, 2' -bipyridine) ruthenium dichloride dihydrate | 昆明贵研新材料科技有限公司 | 2024-01-30 | — | — | CN | claimed |
| CN-114213384-B | Preparation method of 3, 4-disubstituted isocoumarin derivative | 大连大学 | 2023-07-28 | — | — | CN | claimed |
| CN-114195753-B | Preparation method of 3, 4-diphenyl isocoumarin derivative by ruthenium catalysis one-pot method | 大连大学 | 2023-07-28 | — | — | CN | claimed |
| CN-114478627-B | Allylated monophosphine ligand and preparation method thereof | 湖北大学 | 2023-06-20 | — | — | CN | claimed |
| CN-111072577-B | Novel green synthesis method for efficiently synthesizing quinoxaline derivative through transition metal catalyzed carbene insertion/cyclization reaction | 四川大学 | 2023-02-03 | — | — | CN | claimed |
| CN-113754619-B | Method for preparing polysubstituted benzofuran-4-formic acid compound under catalysis of ruthenium | 广州大学 | 2022-12-20 | — | — | CN | claimed |
| CN-112209876-B | Preparation method of 3-trifluoromethyl isoquinolinone derivative | 华侨大学 | 2022-08-26 | — | — | CN | claimed |
| CN-110256332-B | Novel method for synthesizing 1, 2-dihydro-3H-indole-3-ketone derivative | 四川大学 | 2022-07-05 | — | — | CN | claimed |
| CN-111978151-B | Preparation method of 3-methyl-2-butenol | 山东新和成药业有限公司 | 2022-05-17 | — | — | CN | claimed |
| CN-112538573-B | Method for recovering ruthenium from ruthenium-containing waste liquid | 铜陵欣诺科新材料有限公司 | 2022-04-15 | — | — | CN | claimed |
| CN-114213384-A | Preparation method of 3, 4-disubstituted isocoumarin derivative | 大连大学 | 2022-03-22 | — | — | CN | claimed |
| CN-114195753-A | Preparation method for preparing 3, 4-diphenyl isocoumarin derivative by ruthenium catalysis one-pot method | 大连大学 | 2022-03-18 | — | — | CN | claimed |
| EP-1604964-B1 | ZERO-VALENCE TRANSITION METAL COMPLEX AND METHOD OF SYNTHESIZING ORGANOMETALLIC COMPOUND FROM THE SAME AS STARTING MATERIAL | SEKISUI CHEMICAL CO LTD (JP) | 2009-06-10 | — | — | EP | claimed |
| US-7361776-B2 | Zero-valent transition metal complex and method for producing an organometallic compound using the same as a starting material | SEKISUI CHEMICAL CO., LTD. (JP) | 2008-04-22 | — | — | US | claimed |
| US-20060149088-A1 | Zero-valence transition metal complex and method of synthesizing organometallic compound from the same as starting material | SEKISUI CHEMICAL CO., LTD. (JP) | 2006-07-06 | — | — | US | claimed |
| EP-1604964-A1 | ZERO-VALENCE TRANSITION METAL COMPLEX AND METHOD OF SYNTHESIZING ORGANOMETALLIC COMPOUND FROM THE SAME AS STARTING MATERIAL | SEKISUI CHEMICAL CO., LTD. (JP) | 2005-12-14 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060149088-A1 | Zero-valence transition metal complex and method of synthesizing organometallic compound from the same as starting material | OSTC, PORCN, SQLE | ACHE 2404/4885TDP1 4755/4885CHRNA7 1668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.